Treatment of the residual retroperitoneal mass after chemotherapy for advanced seminoma.
Although resection of the residual retroperitoneal mass after chemotherapy for nonseminomatous testicular cancer is standard practice, controversy exists as to the appropriate management of the residual mass after chemotherapy for advanced seminoma. A literature review suggests that 15 to 25 per cent of such masses will contain residual cancer, suggesting that retroperitoneal lymph node dissection is appropriate in these patients.
Ellison
M F
MF
Department of Urology, University of Kentucky Medical Center, Louisville.
Mostofi
F K
FK
Flanigan
R C
RC
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004407:Dysgerminoma / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology / Q000556:secondary*; D005260:Female; D006801:Humans; D008297:Male; D012186:Retroperitoneal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology / Q000556:secondary*; D013736:Testicular Neoplasms / Q000188:drug therapy*; D014057:Tomography, X-Ray Computed